Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
The primary objective of the study is to evaluate the efficacy and the safety of pegfilgrastim versus filgrastim, administered after high-dose chemotherapy and peripheral stem cell reinfusion.
Hematological Neoplasms|Tumors
DRUG: Filgrastim|DRUG: Pegfilgrastim
Duration of aplasia period, At time of discharge from Unit
Immunological reconstitution, 1 year after transplantation
Secondary objective is to evaluate the immunological reconstitution after pegfilgrastim and filgrastim.